Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

729
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
729
Positron Emission Tomography01:29

Positron Emission Tomography

8.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uneven Global Distribution of Theranostics.

World journal of nuclear medicine·2026
Same author

Is There an Added Value of Dual-Time-Point [<sup>68</sup>Ga]Ga-Fibroblast Activation Protein Inhibitor (FAPI) PET/CT in Differentiating Malignant and Benign Uptake Findings?

Cancers·2026
Same author

<sup>68</sup>Ga-FAPI Avidity in Fat Necrosis and Adrenal Adenoma: Expanding the Spectrum of Benign Pitfalls in Oncologic Imaging.

Molecular imaging and radionuclide therapy·2026
Same author

Diagnostic utility of FAPI PET/CT in radioiodine-refractory thyroid cancer and TENIS syndrome: a systematic review.

Oncology reviews·2026
Same author

Detailed pharmacokinetic features of a novel bis-boron <sup>18</sup>F-trifluoroborate acid in healthy volunteers: comparable and additional values of total-body PET-imaging-derived analysis.

European journal of nuclear medicine and molecular imaging·2026
Same author

Precise radiation, better airway preservation: vocal cord-only image-guided intensity-modulated radiation therapy for early-stage glottic cancer.

Frontiers in oncology·2026
Same journal

Diagnostic performance of [18F]FDG PET/CT in large vessel vasculitis management: an umbrella review.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026
Same journal

Evidence-based PET in musculoskeletal infectious and inflammatory diseases.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026
Same journal

Evidence-based data on PET in infectious and inflammatory diseases.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026
Same journal

Evidence-based PET in cardiovascular infectious diseases: an umbrella review.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026
Same journal

Evidence-based role of PET imaging in cardiac and systemic sarcoidosis: an umbrella review of the current literature.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026
Same journal

Response assessment in [177Lu]PSMA: where do we stand?

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.6K

177Lu-PSMA dosimetry made easy: from theory to practical implementation.

Serin Moghrabi1, Krisant Chuamsaamarkkee2, Ahmed Abdlkadir1

  • 1Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Amman, Jordan.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of
|March 19, 2026
PubMed
Summary
This summary is machine-generated.

Personalized dosimetry for 177Lu-PSMA therapy optimizes metastatic castration-resistant prostate cancer (mCRPC) treatment. This framework guides dose estimation to improve efficacy and minimize toxicity for better patient outcomes.

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.8K
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.1K

Related Experiment Videos

Last Updated: Mar 21, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.6K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.8K
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.1K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Medical Physics

Background:

  • 177Lu-PSMA-targeted radioligand therapy (TRT) is a standard of care for metastatic castration-resistant prostate cancer (mCRPC).
  • Optimizing efficacy and minimizing toxicity requires patient-specific internal dosimetry.
  • Current clinical use expansion necessitates practical dosimetry frameworks.

Purpose of the Study:

  • To provide a practical, step-by-step framework for performing 177Lu-PSMA dosimetry.
  • To review evidence correlating absorbed dose with therapeutic response and toxicity.
  • To discuss innovations streamlining dosimetry workflows and advancing personalized dosing.

Main Methods:

  • Review of existing literature and clinical practices for 177Lu-PSMA dosimetry.
  • Description of the process from radioligand administration to absorbed dose estimation.
  • Analysis of technological advancements and ongoing trials.

Main Results:

  • Strong correlation exists between tumor absorbed dose and therapeutic response.
  • Established dose thresholds for organs at risk (kidneys, salivary glands, bone marrow) guide safe administration.
  • Innovations like DL-assisted reconstruction and automated pipelines are simplifying dosimetry.

Conclusions:

  • Patient-specific dosimetry is crucial for maximizing safety and effectiveness of 177Lu-PSMA therapy.
  • Personalized dosimetry enables optimized treatment planning and improved patient outcomes.
  • Ongoing advancements are integrating dosimetry seamlessly into routine clinical practice.